PUT/ELI LILLY & CO/600/0.1/16.01.26 | Market Closed - BOERSE MUENCHEN 11:56:07 10/07/2024 pm IST | ||
| 1.84 EUR | +4.55% |
|
| Current month | +3.95% | ||
| 1 month | -23.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 10/24/10 | 1.84 | +4.55% |
| 09/24/09 | 1.76 | -1.12% |
| 08/24/08 | 1.78 | -6.81% |
| 05/24/05 | 1.91 | -6.37% |
| 04/24/04 | 2.04 | +0.49% |
Real-time BOERSE MUENCHEN
Last update July 10, 2024 at 11:56 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Goldman Sachs |
| WKN | GG6DGD |
| ISIN | DE000GG6DGD7 |
| Date issued | 02/04/2024 |
| Strike | 600 $ |
| Maturity | 16/01/2026 (555 Days) |
| Parity | 10 : 1 |
| Emission price | 4.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.24 € |
|---|---|
| Lowest since issue | 1.64 € |
| Spread | 0.15 € |
| Spread % | 7.58% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
874.8
USD
Spread / Average Target
-6.92%
- Stock Market
- Warrants
- Warrant
